AmberGen is a privately-held biotechnology company that is developing a
new generation of diagnostic tests.
AmberGen's proprietary molecular
profiling technology enables physicians to more accurately make optimal
therapeutic decisions tailored to individual patients. This is made
possible by identifying unique molecular fingerprints in tumors, blood
and other biospecimens that are characteristic of specific diseases and
their outcomes. AmberGen approach combines unique patented technology
in the area of proteomics, genomics and bioinformatics.